Upstream Bio (UPB) Projected to Announce Quarterly Earnings on Wednesday

Upstream Bio (NASDAQ:UPB) is expected to be announcing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to announce earnings of ($0.78) per share and revenue of $0.4310 million for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 9:30 AM ET.

Upstream Bio (NASDAQ:UPB) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.02). The business had revenue of $1.03 million during the quarter, compared to the consensus estimate of $1.03 million. Upstream Bio had a negative return on equity of 43.82% and a negative net margin of 4,718.96%. On average, analysts expect Upstream Bio to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Upstream Bio Price Performance

Shares of Upstream Bio stock opened at $6.31 on Monday. The business’s fifty day moving average price is $6.99 and its two-hundred day moving average price is $11.47. The company has a market capitalization of $343.39 million, a P/E ratio of -2.17 and a beta of 1.26. Upstream Bio has a 1-year low of $5.85 and a 1-year high of $33.68.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Nuveen LLC raised its position in Upstream Bio by 12.4% in the fourth quarter. Nuveen LLC now owns 78,568 shares of the company’s stock worth $2,133,000 after acquiring an additional 8,686 shares in the last quarter. SummitTX Capital L.P. bought a new position in shares of Upstream Bio during the 3rd quarter valued at about $2,114,000. Exome Asset Management LLC boosted its position in shares of Upstream Bio by 24.8% during the 4th quarter. Exome Asset Management LLC now owns 64,845 shares of the company’s stock valued at $1,761,000 after purchasing an additional 12,885 shares in the last quarter. Alps Advisors Inc. grew its stake in shares of Upstream Bio by 70.9% in the 4th quarter. Alps Advisors Inc. now owns 44,376 shares of the company’s stock worth $1,205,000 after purchasing an additional 18,414 shares during the last quarter. Finally, Rafferty Asset Management LLC grew its stake in shares of Upstream Bio by 12.1% in the 4th quarter. Rafferty Asset Management LLC now owns 38,683 shares of the company’s stock worth $1,050,000 after purchasing an additional 4,162 shares during the last quarter.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on UPB shares. HC Wainwright initiated coverage on Upstream Bio in a research note on Wednesday, June 3rd. They issued a “buy” rating and a $36.00 price target for the company. Mizuho dropped their price target on shares of Upstream Bio from $51.00 to $50.00 and set an “outperform” rating on the stock in a research report on Thursday, May 14th. JPMorgan Chase & Co. lowered shares of Upstream Bio from an “overweight” rating to a “neutral” rating and reduced their price target for the stock from $35.00 to $8.00 in a research note on Friday, June 12th. Finally, Weiss Ratings cut shares of Upstream Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 6th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Upstream Bio currently has an average rating of “Hold” and a consensus price target of $33.17.

About Upstream Bio

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.